Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus Post author:sritekinc9 Post published:May 20, 2020 Post category:Uncategorized Post comments:0 Comments CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 18, 2020– Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). You Might Also Like April’s U.S. hiring plunged 23.9% May 7, 2020 USCIS-ITServe Settlement Overturns 10 Years Of H-1B Visa Policies May 21, 2020 USCIS Resumes Premium Processing for Certain Petitions June 4, 2020 Leave a Reply Cancel replyCommentEnter your name or username to comment Enter your email address to comment Enter your website URL (optional) Save my name, email, and website in this browser for the next time I comment. This site uses Akismet to reduce spam. Learn how your comment data is processed.
